Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, Jalisco, México.
Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, Jalisco, México; Unidad de Evaluación Preclínica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, Jalisco, México.
Neurologia (Engl Ed). 2020 Apr;35(3):147-154. doi: 10.1016/j.nrl.2017.07.016. Epub 2017 Nov 11.
Chronic kidney disease (CKD) can cause anaemia and neurological disorders. Recombinant human erythropoietin (rHuEPO) is used to manage anaemia in CKD. However, there is little evidence on the effects of rHuEPO on behaviour and cognitive function in CKD. This study aimed to evaluate the impact of rHuEPO in sensorimotor and cognitive functions in a CKD model.
Male Wistar rats were randomly assigned to 4 groups: control and CKD, with and without rHuEPO treatment (1050 IU per kg body weight, once weekly for 4 weeks). The Morris water maze, open field, and adhesive removal tests were performed simultaneously to kidney damage induction and treatment. Markers of anaemia and renal function were measured at the end of the study.
Treatment with rHuEPO reduced kidney damage and corrected anaemia in rats with CKD. We observed reduced sensorimotor dysfunction in animals with CKD and treated with rHuEPO. These rats also completed the water maze test in a shorter time than the control groups.
rHuEPO reduces kidney damage, corrects anemia, and reduces sensorimotor and cognitive dysfunction in animals with CKD.
慢性肾脏病（CKD）可引起贫血和神经紊乱。重组人促红细胞生成素（rHuEPO）用于治疗 CKD 引起的贫血。然而，关于 rHuEPO 对 CKD 患者行为和认知功能的影响的证据很少。本研究旨在评估 rHuEPO 对 CKD 模型中感觉运动和认知功能的影响。
雄性 Wistar 大鼠随机分为 4 组：对照组和 CKD 组，rHuEPO 治疗组（1050IU/kg 体重，每周 1 次，共 4 周）。在诱导和治疗肾脏损伤的同时进行 Morris 水迷宫、旷场和粘取试验。在研究结束时测量贫血和肾功能的标志物。
rHuEPO 治疗可减轻 CKD 大鼠的肾脏损伤并纠正贫血。我们观察到 rHuEPO 治疗的 CKD 动物的感觉运动功能障碍减少。这些大鼠在水迷宫测试中完成的时间也比对照组短。
rHuEPO 可减轻 CKD 动物的肾脏损伤，纠正贫血，并减轻感觉运动和认知功能障碍。
